RxDoctor Payments Data

Ana Cole, PA

Physician Assistant · Las Vegas, NVNPI 1033998679

Payments from drug & device makers

$1,287in general payments, 2019–2025

Across 43 payments — averaging $29.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$335
  • Globus Medical$252
  • Pfizer$232
  • Boston Scientific$179
  • SPR Therapeutics, Inc$175
  • Forte Bio-pharma LLC$64
  • plus $50 from 2 others

What the payments were for

  • Travel & lodging$1048%
  • Food & beverage$1,18392%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie16$335
Globus Medical4$252
Pfizer12$232
Boston Scientific2$179
SPR Therapeutics, Inc3$175
Forte Bio-pharma LLC3$64
Protega Pharmaceutials Inc2$32
Scilex Pharmaceuticals Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,287 in reported general payments places this provider in the 65th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$42,967
Medicare patients
135
Services billed
586

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant18$19,340
QuliptaAtogepant12$13,009
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen188$7,726
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen350$7,421
LinzessLinaclotide12$7,032
Diclofenac Sodium44$4,293
Lidocaine36$4,289
Pregabalin127$2,675
Oxycodone Hcl112$1,973
Duloxetine Hcl95$976
Gabapentin109$936
Tizanidine Hcl102$482
Lidocaine-PrilocaineLidocaine/Prilocaine14$393
Cyclobenzaprine Hcl50$385
Morphine Sulfate ErMorphine Sulfate19$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Linzess$335$39,38142 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →